Cougar Biotechnology Announces CB7630 Phase I Data to Be Presented at National Cancer Research Institute Conference.LOS ANGELES -- Cougar cougar: see puma. cougar or puma or mountain lion or panther Species (Puma concolor) of large, graceful cat that lives in a wide variety of habitats in the Americas, from southern Alaska to Patagonia. Biotechnology, Inc., a publicly held biotechnology company, today announced that Phase I data on the Company's prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. drug CB7630 (abiraterone acetate) will be presented at National Cancer Research Institute (NCRI NCRI National Council of Resistance of Iran NCRI National Cereals Research Institute (Nigeria) ) Cancer Conference that will take place October 8-11, 2006 in Birmingham, UK. The presentation, which will take place during the plenary session on October 8th, is entitled "Inhibition of androgen synthesis by an oral, irreversible, inhibitor of CYP CYP In currencies, this is the abbreviation for the Cyprus Pound. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 450c17 appears safe and results in a high, durable, response rate in castration castration, removal of the sex glands of an animal, i.e., testes in the male, or ovaries and often the uterus in the female. Castration of the female animal is commonly referred to as spaying. refractory prostate cancer (CRPC) patients" and will be presented by Dr. Johann S. deBono, MSc, PhD, MD, FRCP FRCP Fellow of the Royal College of Physicians. FRCP abbr. Fellow of the Royal College of Physicians from the Institute of Cancer Research and Royal Marsden Hospital in Sutton, UK. Further information about the NCRI conference and the presentation can be found at: http://www.ncri.org.uk/ncriconference/programme/01day/Prog_DayOne.htm. "The NCRI conference is the largest annual conference on cancer in the United Kingdom. We are pleased to be able to present this data at such a well respected international conference," said Dr. Arie Belldegrun, MD, FACS FACS Fellow of the American College of Surgeons. FACS abbr. Fellow of the American College of Surgeons FACS fluorescence-activated cell sorter. , Vice Chairman of the Board of Directors of Cougar Biotechnology. Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "This will represent the first public presentation of data for CB7630 as a second line hormonal agent for patients with advanced prostate cancer who have failed treatment with first line hormonal therapy. As this continues to be a patient group that is underserved by current treatments, we look forward to the continued development of CB7630 in this area." About Cougar Biotechnology Cougar Biotechnology, Inc. is a Los Angeles-based publicly held biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase lyase /ly·ase/ (li´as) any of a class of enzymes that remove groups from their substrates (other than by hydrolysis or oxidation), leaving double bonds, or that conversely add groups to double bonds. enzyme which is currently being tested in a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I in prostate cancer; CB3304, an inhibitor of microtubule microtubule Tubular structure enclosed by a membrane found within animal and plant cells. Of varying length, they have several functions. They help give shape to many cells and are major components of cilia and flagella, participate in the formation of the spindle during dynamics which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D which has been clinically tested in a number of solid tumor types. Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com. This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Cougar's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Cougar's product candidates, the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 7, 2006. Cougar assumes no obligation to update these statements, except as required by law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion